Open AccessAmyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression
Author(s) -
Hongchun Wei,
Bing Li,
Kok Pin Ng,
Qingxi Fu,
Shengjie Dong,
Bâ M,
Min Kong
Publication year - 2021
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001496
Subject(s) - biomarker , dementia , medicine , clinical dementia rating , psychology , positron emission tomography , neuroimaging , magnetic resonance imaging , standardized uptake value , oncology , cardiology , neuroscience , disease , radiology , biochemistry , chemistry
According to the amyloid, tau, neurodegeneration research framework classification, amyloid and tau positive (A+T+) mild cognitive impairment (MCI) individuals are defined as prodromal Alzheimer disease. This study was designed to compare the clinical and biomarker features between A+T+MCI individuals who progressed to progressive MCI (pMCI) and those who remained stable MCI (sMCI), and to identify relevant baseline clinical biomarker and features that could be used to predict progression to dementia within 2 years.